learndrugs
Immune / Infectious

Systemic Lupus Erythematosus

SLE Verified · Oct 2026

Systemic lupus erythematosus is a chronic, systemic autoimmune inflammatory disease in which autoantibodies form immune complexes that deposit in tissue, consume complement, and inflame multiple organs — skin, joints, kidneys, blood, lungs, heart, and nervous system.

The disorder behind the butterfly rash that spares the nasolabial folds, the ANA that screens but never diagnoses, the rising anti-dsDNA with falling complement, the kidney that fails without a symptom, and the sunscreen prescription that is genuinely a prescription.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 Type III hypersensitivity — the mechanism that dictates the organ list

Lupus is the clinical face of a type III (immune-complex) hypersensitivity reaction, and the reaction runs in three steps. First, IgG or IgM antibodies form within 7 to 10 days and bind soluble antigen, creating antigen–antibody complexes that circulate. Second, those complexes deposit in tissue — and they deposit precisely because they are small: "macrophages do not efficiently clear small immune complexes." Third, the deposited complexes "activate the classical complement pathway, generating C3a and C5a," which recruit inflammatory cells that "release proteolytic enzymes and reactive oxygen species," damaging the tissue they were called to.

Where the complexes land explains the whole lupus organ list. The sourced deposition sites are "glomeruli, synovia, blood vessels, or alveoli" — kidney, joint lining, small vessel, lung. That is not a coincidental overlap; it is the same sentence read twice. Autoantibody damage then proceeds by the final common pathway of "immune complex deposition, complement activation, neutrophil recruitment, and altered cell function."

The mechanism leaves a laboratory footprint that a nurse can read: "Complement consumption results in low serum C3, C4, and CH50." This is the single most useful conceptual correction on the page — low complement in lupus is not a deficiency, it is consumption. The complement was used up binding immune complexes, so a falling C3 and C4 means the reaction is currently running. "Low complement levels indicate complement consumption and may correlate with disease activity," which is why complement is checked alongside anti-dsDNA at every activity assessment.

The type III hypersensitivity chain in lupus: small immune complexes escape clearance, deposit in glomeruli, synovia, vessels and alveoli, and activate complement — which is consumed, producing the low C3 and C4 of active disease.

02 Where the self-antigen comes from — and why sunlight is a drug-level exposure

A type III reaction needs an antigen supply, and in lupus the supply is the patient’s own cell nuclei. "Impaired clearance of neutrophil extracellular traps and apoptotic debris provides a persistent source of autoantigens." That single sentence turns ultraviolet light from a lifestyle footnote into a mechanism: "Ultraviolet radiation and sun exposure increase cell apoptosis and are well-known triggers of SLE flare." More apoptosis means more nuclear material released, which means more antigen for the autoantibodies already circulating.

Two arms of the immune system then amplify it. On the innate side, Toll-like receptor pathways, especially TLR7 and TLR9 in plasmacytoid dendritic cells, trigger robust type I interferon production, with cGAS, STING, RIG-I and MDA5 amplifying the response — the interferon signature that anifrolumab targets. On the adaptive side, abnormal T-cell activation produces "dysregulated gene expression and reduced IL-2 production," crippling regulatory T cells, while "autoreactive B cells are not efficiently eliminated due to defective tolerance mechanisms." The result is described exactly as it behaves: "a self-perpetuating cycle of B- and T-cell activation that sustains chronic autoimmunity" — the rationale for B-cell-directed therapy.

Because the cycle is self-perpetuating, the practical teaching point is about duration, not just avoidance. Photosensitivity is present "in more than 90% of cases" and is "an abnormal skin reaction to ultraviolet A and ultraviolet B radiation, as well as visible light, that may last for weeks to months." One afternoon at the beach can drive a flare that outlasts the sunburn by a season. That is why photoprotection in lupus is specified with numbers — broad-spectrum sunscreen at SPF at least 70 for chemical sunscreens and at least 50 for physical blockers, plus lightweight, loose-fitting, dark clothing covering as much skin as possible.

The flare cycle: ultraviolet light increases apoptosis and releases nuclear autoantigen, interferon and defective tolerance amplify the autoantibody response, and the resulting tissue injury feeds more antigen back into the loop.

03 Lupus nephritis — the organ that fails without telling anyone

The kidney is where lupus does its quietest and most consequential damage. The chain is specific: anti-dsDNA "antibodies bind to DNA, which forms anti-dsDNA immune complexes" that deposit in glomerular regions, activate complement and trigger inflammation. That is why anti-dsDNA titre and complement levels track kidney activity rather than merely correlating with it. Nephritis occurs in roughly 40% to 50% of patients with SLE — the two professional sources give 40% and 50%, so the range is what should be taught — and it "usually occurs early in the course of SLE."

The danger is that early lupus nephritis is silent: "In the early stages of lupus nephritis, patients are often asymptomatic." When symptoms finally arrive they are "new-onset hypertension, hematuria, proteinuria, lower extremity edema, and elevated creatinine," plus "polyuria, nocturia, foamy urine, hypertension, and edema" — but by then the inflammation has been running. This is the single strongest argument for scheduled monitoring in the whole disorder: lupus nephritis is detected by urinalysis and creatinine, not by how the patient feels. The urinalysis findings to know are proteinuria, microscopic hematuria, or red blood cell casts, with quantification by 24-hour urine protein or a spot protein-to-creatinine ratio.

The biopsy is not optional and the class is not academic. Renal biopsy should "always be performed when lupus nephritis is suspected," and is specifically indicated with proteinuria above roughly 500 mg per 24 hours, persistent renal dysfunction, or active urinary sediment — because it helps "stage the disease and direct management." The ISN/RPS classes run from Class I (minimal mesangial, normal light microscopy) and Class II (mesangial proliferative) through Class III (focal, under 50% of glomeruli) and Class IV (diffuse, about 50% or more — the worst prognosis) to Class V (membranous, presenting as nephrotic syndrome) and Class VI (advanced sclerosing, 90% or more globally sclerosed). Outcomes are "excellent… for Classes I and II and less favorable… for Classes III and IV," and the prognostic number to track afterwards is proteinuria: a 1-year cutoff of 0.7 to 0.8 g per 24 hours predicts good long-term renal prognosis.

Lupus nephritis: anti-dsDNA immune complexes inflame the glomerulus long before any symptom appears, which is why scheduled urinalysis and creatinine — not the patient’s report — are what find it.

04 Two hits — and the lupus that goes away when you stop the drug

A "2-hit hypothesis" organizes the risk factors: a first hit breaks immune tolerance, and a second, environmental hit triggers the florid autoimmune response. The first hit is largely who the patient is. The female-to-male ratio is 9 to 1, the disease "predominantly affects women of childbearing age," and risk falls after menopause; estrogen receptors "are expressed throughout the immune system," and estrogens have been shown to "stimulate B-cell production of IgA, IgG, and IgE," and risk is 14-fold higher in Klinefelter syndrome (47,XXY) — which points at X-chromosome dosage rather than at estrogen alone. Black populations have the highest rates, followed by Asian and Hispanic, then White populations, with greater severity and earlier onset in Black patients. And the sex paradox worth remembering: lupus is less common in men but "lupus in men tends to be more severe," with male sex a poor prognostic factor.

The second hit is what the patient encounters. Sourced environmental triggers: ultraviolet radiation, smoking, silica exposure, air pollution, vitamin D deficiency, alfalfa sprouts and canavanine-containing foods, and infections implicated by molecular mimicry — Epstein-Barr virus, cytomegalovirus, COVID-19. Smoking earns special emphasis because it works on both ends: it "exacerbates SLE activity, and cessation must be strongly encouraged," and smoking cessation "was associated with lower SLE disease activity."

Drug-induced lupus is the version that reverses, and it is the reason a medication history belongs in every lupus work-up. Up to 20% of patients on long-term procainamide and 5% to 10% of those on hydralazine develop lupus-like symptoms; other well-established agents include isoniazid, rifampin, minocycline, quinidine, phenytoin, methyldopa, chlorpromazine, penicillamine, carbamazepine, propylthiouracil and sulfasalazine, with all TNF inhibitors and immune checkpoint inhibitors as emerging causes. It presents with "arthralgia, myalgia, fever, serositis, and fatigue," and — the discriminating feature — "renal and central nervous system involvement occur less frequently than in primary lupus." Symptoms begin weeks to months after the drug starts and resolve within weeks to months of stopping it, which makes discontinuation the cornerstone of management, though "autoantibodies may remain positive long after clinical improvement."

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Female sex — a 9 to 1 female-to-male ratio, predominantly affecting women of childbearing age, with risk falling after menopause Black race — the highest rates, with greater disease severity and earlier onset; then Asian and Hispanic, then White populations Male sex as a severity modifier — less common, but "lupus in men tends to be more severe" and male sex is a poor prognostic factor X-chromosome dosage — risk is 14-fold higher in Klinefelter syndrome (47,XXY) Ultraviolet radiation and sun exposure — the best-established flare trigger, acting by increasing apoptosis modifiable Smoking — "exacerbates SLE activity, and cessation must be strongly encouraged"; cessation is associated with lower disease activity modifiable Silica exposure and air pollution modifiable Vitamin D deficiency modifiable Alfalfa sprouts and other canavanine-containing foods modifiable Infection by molecular mimicry — Epstein-Barr virus, cytomegalovirus, COVID-19 Pregnancy — approximately 25% of patients flare during pregnancy modifiable Drug-induced lupus — procainamide (up to 20% on long-term therapy) and hydralazine (5% to 10%) are the highest-risk agents modifiable Other drug causes — isoniazid, rifampin, minocycline, quinidine, phenytoin, methyldopa, chlorpromazine, penicillamine, carbamazepine, propylthiouracil, sulfasalazine, interferon-α modifiable Emerging drug causes — all TNF inhibitors (etanercept, infliximab, adalimumab, golimumab, certolizumab) and immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) modifiable

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Fatigue, malaise, fever, anorexia and weight loss — present in more than 90% of patients early Hold & notify
Why: Systemic cytokine-driven inflammation. These constitutional symptoms are the most common manifestation of lupus and are "often the initial presenting features" — the butterfly rash is the famous sign, but this is the usual one. A new fever in a patient on immunosuppressants is escalated, because infection and flare look identical.
Malar ("butterfly") rash — raised erythema across the cheeks and nasal bridge that spares the nasolabial folds and heals without scarring Expected
Why: Photodistributed acute cutaneous lupus — the immune-complex reaction in sun-exposed skin. The nasolabial sparing is the diagnostic detail: it is what separates the lupus malar rash from look-alikes. Note the frequency trap — acute cutaneous lupus accounts for only about 15% of cutaneous cases, so this is the distinctive sign, not the common one.
Photosensitivity — an abnormal reaction to UVA, UVB and visible light that may last weeks to months Expected
Why: UV light increases apoptosis, releasing nuclear autoantigen that feeds the autoantibody cycle. Present in more than 90% of cases. The duration is the teaching point: one exposure can drive a flare lasting a season, which is why photoprotection is preventive rather than cosmetic.
Discoid lesions — disc-shaped erythematous plaques with adherent scaling and central clearing, present in about 20% of patients with SLE Hold & notify
Why: Chronic cutaneous lupus. Unlike the malar rash, these heal with scarring and cause permanent alopecia when they sit on the scalp — active inflammation at the periphery leaves depressed central atrophy. Early treatment is what prevents permanent disfigurement.
Oral ulcers on the hard palate, buccal mucosa or vermilion border — and they are often painless at first Expected
Why: Mucosal immune-complex injury. The painlessness is precisely why they are missed: a patient who is asked "does your mouth hurt?" will say no. Inspect the mouth rather than asking about it.
Symmetric, nonerosive inflammatory polyarthritis of the small hand joints, wrists and knees — in 80% to 90% of patients at some point Expected
Why: Immune complexes deposit in synovium. Jaccoud arthropathy produces ulnar deviation and metacarpophalangeal subluxation from "joint capsule and ligament laxity" — and it is usually reducible. Only about 3% to 5% of patients develop erosive disease. This is the contrast with rheumatoid arthritis, where the deformity is erosive and fixed.
Sharp chest pain worse with breathing — pleurisy, pleural effusion or pericarditis Hold & notify
Why: Serositis. Pulmonary involvement affects almost 50% of patients, and pericarditis is the most common cardiac manifestation. Pleuritic chest pain in a lupus patient is evaluated, not reassured away — and in a young woman with lupus, chest pain is also not automatically musculoskeletal, because accelerated atherosclerosis is real.
Cytopenias — leukopenia < 4,000 cells/mm³, lymphopenia < 1,500 cells/mm³, thrombocytopenia < 100,000/mm³ Hold & notify
Why: Autoimmune hemolytic anemia, immune-mediated destruction, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and drug or infection causes all contribute; marrow failure from myelofibrosis, aplastic anemia or pure red cell aplasia also occurs. Each of these values also carries classification-criterion weight.
A new clot — deep vein thrombosis, pulmonary embolism, or an arterial event Report immediately
Why: Thrombosis occurs in more than 10% of patients, and antiphospholipid antibodies — anticardiolipin, β2-glycoprotein-1, lupus anticoagulant — are "associated with both arterial and venous clots." In a young patient with lupus, a clot is a disease manifestation rather than an unlucky coincidence.
Nothing at all from the kidney — or, later, new hypertension, foamy urine, nocturia and leg edema Hold & notify
Why: Lupus nephritis affects roughly 40% to 50% of patients and usually appears early, but the early stages "are often asymptomatic." By the time edema and hypertension arrive, the glomerulus has been inflamed for a while. This is why scheduled urinalysis and creatinine — not symptoms — drive detection.
Intractable headache — reported in more than 50% of neuropsychiatric lupus cases Hold & notify
Why: The ACR defines 19 neuropsychiatric manifestations, affecting up to 20% of patients, and headache is the most common of them. Cerebrovascular disease "may occur, contributing to mortality in up to 15% of patients," so a headache in lupus is not automatically benign.
New seizure, psychosis, acute confusion or a focal neurologic deficit Report immediately
Why: Neuropsychiatric lupus spans cognitive dysfunction and seizures through chorea, acute confusional states, aseptic meningitis, demyelinating disease and transverse myelitis, with psychiatric presentations "from depression and anxiety to frank psychosis." Inflammatory CNS disease is treated with high-dose pulse corticosteroids — this is an escalate-now finding.
Alopecia — two kinds, with opposite prognoses Expected
Why: Scarring alopecia from discoid lesions is permanent; non-scarring "brittle, easily breaking lupus hair" in the temporal and parietal areas recovers with disease control. Telling the patient which one they have is the difference between grief and reassurance.
Pale or purple fingers and toes on cold exposure — Raynaud phenomenon Expected
Why: Listed among the non-specific mucocutaneous manifestations of lupus, alongside cutaneous vasculitis, livedo reticularis, superficial thrombophlebitis, periungual erythema and urticaria. Teach cold avoidance; the fetched sources do not support a more detailed colour-phase description.

Diagnostics

Test In this disorder Normal
Antinuclear antibody (ANA) The asymmetry is the whole teaching point: a positive ANA "is not diagnostic, but a negative result makes SLE highly unlikely." Immunofluorescence assay is the gold-standard method; ELISA and multiplex are less sensitive. Rare ANA-negative SLE exists. No ANA, no classification — but a positive ANA alone is not lupus The screening test and the entry criterion — sensitivity greater than 97% of SLE cases, but specificity only about 20% 2019 EULAR/ACR criteria, as reported by StatPearls Entry criterion for classification: at least 1:80 on HEp-2 cells or a positive equivalent test
Anti-double-stranded DNA (anti-dsDNA) Correlates with disease activity and with the development of lupus nephritis, though it may be elevated in minimally active disease. ELISA carries "a high risk of false-positive results," with the Crithidia luciliae immunofluorescence test used for confirmation. Also seen in drug-induced lupus from anti-TNF agents and interferon-α Greater than 95% specificity for SLE, but present in only about 40% to 80% of patients — "a negative anti-dsDNA result does not rule out the diagnosis of SLE" —
Anti-Smith (anti-Sm) Pair it with anti-dsDNA as the specific antibodies — low sensitivity, very high specificity — against ANA as the sensitive one. In the 2019 EULAR/ACR weighting, anti-dsDNA or anti-Sm carries 6 points, the single heaviest immunologic weight Present in only 10% to 55% of patients — but with 99% specificity for SLE; more frequently seen in Black individuals 2019 EULAR/ACR criteria, as reported by StatPearls —
Complement C3 and C4 "C3 and C4 should be checked in patients with SLE or suspected SLE"; low levels "indicate complement consumption and may correlate with disease activity." The flare signature to recognize: rising anti-dsDNA with falling C3 and C4. In the classification criteria, low C3 or C4 scores 4 points Low in active disease — complement is consumed binding immune complexes, not deficient 2019 EULAR/ACR criteria, as reported by StatPearls —
Urinalysis with protein quantification This is the test that finds the silent kidney. Also expect hypoalbuminemia and a rising serum creatinine as nephritis advances. Proteinuria is the prognostic number afterwards — a 1-year cutoff of 0.7 to 0.8 g/24 h predicts good long-term renal prognosis Proteinuria, microscopic hematuria, or red blood cell casts; quantify with a 24-hour urine protein or spot urine protein-to-creatinine ratio —
Renal biopsy Indicated with proteinuria above roughly 500 mg per 24 hours, persistent renal dysfunction, or active urinary sediment. Class IV (diffuse, about 50% or more of glomeruli) carries the worst prognosis; Classes I and II have excellent outcomes. Lupus nephritis is comanaged with a nephrologist in every case Should "always be performed when lupus nephritis is suspected" — histopathology, immunofluorescence and electron microscopy set the ISN/RPS class, and the class sets the therapy —
CBC, chemistry, inflammatory markers Drawn at every activity assessment alongside creatinine and urinalysis. A falling platelet count or new anemia may be lupus, its treatment, or an infection — which is why they are interpreted against complement and anti-dsDNA rather than alone Cytopenias (leukopenia < 4,000/mm³, lymphopenia < 1,500/mm³, thrombocytopenia < 100,000/mm³); CRP and ESR frequently elevated; polyclonal hypergammaglobulinemia —
Antiphospholipid antibody panel and other specific antibodies All pregnant patients with SLE are tested for antiphospholipid antibodies and for anti-SSA/Ro and anti-SSB/La — the results change obstetric management. Anti-ribosomal P is highly specific but rare (< 5%) and may correlate with neuropsychiatric disease; anti-U1-RNP appears in 20% to 40% and also defines mixed connective tissue disease Lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I — "associated with thrombotic events and adverse pregnancy-related outcomes." Anti-SSA/Ro and anti-SSB/La carry congenital heart block and neonatal lupus risk —

Complications

Warning: Cardiovascular disease — now the leading cause of death Report immediately
Accelerated atherosclerosis and premature cardiovascular events, "particularly in younger patients," driven by chronic inflammation, immune dysregulation and antiphospholipid antibodies.
Cardiovascular disease "accounts for about half of deaths in Western cohorts" and is explicitly "further exacerbated by glucocorticoid therapy" as well as by traditional risk factors — which is why steroid-sparing is a survival strategy, not a comfort measure. The clinical consequence: chest pain in a young woman with lupus is not automatically costochondritis. Blood pressure, lipids, weight and smoking status belong in every visit.
Warning: Lupus nephritis progressing to end-stage kidney disease Hold & notify
Roughly 10% to 30% of patients with lupus nephritis progress to end-stage kidney disease within 10 years — the range the two professional sources jointly support.
Nephritis is the second-ranked cause of morbidity and mortality after cardiovascular disease. Outcomes depend on the ISN/RPS class and on how early it is caught, which is a monitoring problem rather than a treatment problem — the early disease is asymptomatic. Transplant changes the picture markedly: approximately 16.9% mortality among transplanted patients versus 51.6% among those not transplanted, and "recurrent lupus nephritis after renal transplant is very rare."
Warning: Serious and opportunistic infection Report immediately
Infection is a leading cause of morbidity and mortality, due to "both immune dysfunction and immunosuppressive therapy," with added risk from active disease, kidney injury, lymphopenia and diabetes.
Mycobacterial and fungal opportunistic infections occur alongside ordinary ones. The clinical rule that follows: fever in a lupus patient on immunosuppressants is infection until proven otherwise — and because a flare produces the same fever, fatigue and malaise, the two cannot be distinguished at the bedside. Report it rather than treating it as a flare.
Caution: Glucocorticoid toxicity and malignancy
Steroid exposure brings "osteoporosis, glaucoma, cataracts, weight gain, skin striae, and diabetes mellitus, with sequelae of those complications"; lupus itself raises cancer risk, with non-Hodgkin lymphoma most common and higher rates of cervical dysplasia.
In a patient diagnosed in her twenties and facing decades of disease, steroid toxicity is a lifetime burden, not a short-course inconvenience — which is why the guideline taper target exists and why immunosuppressants are introduced specifically to spare steroids. All patients need "regular monitoring for comorbid conditions": infections, cardiovascular disease, osteoporosis, malignant neoplasms and reproductive health.
Caution: Pregnancy complications and permanent skin damage
Fetal loss, preeclampsia, eclampsia, congenital heart block and neonatal lupus — "especially in women with active disease." Separately, scarring, dyspigmentation and alopecia cause lasting disfigurement.
Congenital heart block risk with anti-SSA/Ro or anti-SSB/La is 1% to 2% for a first pregnancy but 17% for subsequent pregnancies, and complete heart block "is irreversible and requires a permanent pacemaker in the infant." Patients with pulmonary hypertension, severe cardiovascular disease or prior stroke are at very high risk of maternal mortality. Permanent skin damage causes "significant reduction in quality of life, depression, and anxiety" — psychiatric complications are common and adversely affect health-related quality of life.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Corticosteroids First-line
Endocrine · prednisone

The fast tool for organ-threatening inflammation — and the one with an explicit exit plan. Short courses treat ongoing or recurrent inflammatory arthritis; moderate doses treat pleuropericarditis; high-dose intravenous pulse corticosteroids treat acute lupus pneumonitis, severe or symptomatic thrombocytopenia, and inflammatory CNS manifestations; combinations with cyclophosphamide, mycophenolate or rituximab treat myocarditis, and with IVIG or rituximab treat hemolytic anemia. The taper target is a guideline number, not a preference: the ACR-based lupus-nephritis regimen tapers to approximately 5 mg/day of prednisone-equivalent by the 6-month mark, with maintenance below 7.5 mg/day if steroids are used at all. On provenance, two honest caveats: the StatPearls carrier reporting this does not name its ACR edition, and ACR has since published a 2024 lupus-nephritis guideline and a 2025 lupus guideline whose full texts are not open — their abstracts stress limiting how long glucocorticoids are used and, in nephritis, continuous therapy with pulse steroids, an oral taper and two added immunosuppressants for 3–5 years in patients who reach a complete renal response, but they give no taper number — while the same ≤ 5 mg/day-within-6-months target is independently carried by the EULAR 2023 recommendations, so the number has recent corroboration from a second society. That number exists because glucocorticoids exacerbate the accelerated atherosclerosis that already kills about half of these patients, and add osteoporosis, glaucoma, cataracts, weight gain and diabetes on top — a real cost in someone facing fifty more years of disease.
Immunosuppressants / Biologics / DMARDs First-line
Immune / Anti-infective · methotrexate

Two jobs at once: control organ-threatening disease, and get the patient off steroids — "corticosteroid-sparing medications" are named as the mainstay for ongoing arthritis, and inadequate response or glucocorticoid dependency is itself the trigger to introduce them earlier. Choice follows the organ: methotrexate, mycophenolate mofetil or azathioprine for arthritis beyond hydroxychloroquine; methotrexate then mycophenolate, belimumab or anifrolumab for resistant cutaneous disease; high-dose corticosteroids plus cyclophosphamide, azathioprine or rituximab for inflammatory CNS disease; mycophenolate or rituximab for interstitial lung disease. Lupus nephritis is where this class is unambiguously first-line: new or flaring Class III–IV disease now gets triple therapy: glucocorticoids plus mycophenolate with belimumab or a calcineurin inhibitor such as voclosporin, or cyclophosphamide followed by mycophenolate plus belimumab (ACR, as reported by StatPearls), with an anti-CD20 agent such as rituximab or obinutuzumab for refractory disease, always with hydroxychloroquine and always comanaged with a nephrologist. Maintenance runs at least 3 years in nephritis, and immunosuppression is generally continued 3 to 5 years with sustained remission before tapering. The price is infection risk — serious infection is one of the leading causes of morbidity and mortality in lupus — so every fever is taken seriously. In pregnancy, disease should be quiescent 6 months or more before conception, teratogenic agents switched 4 to 6 months ahead, and azathioprine used as the steroid-sparing agent.
NSAIDs
Musculoskeletal · ibuprofen

The symptom-control tool for the mild end only — "For minor arthralgias, NSAIDs may be used" — and one component of pleuropericarditis management alongside colchicine or moderate-dose corticosteroids, with escalation to hydroxychloroquine, mycophenolate or azathioprine when pericarditis recurs despite them. The disorder-specific caution is not a stated contraindication but an intersection the nurse must hold in mind: roughly 40% to 50% of these patients develop nephritis, often silently, and lupus drives accelerated atherosclerosis — so NSAIDs are given against a background of renal and cardiovascular vulnerability. Monitor renal function and blood pressure rather than assuming an over-the-counter analgesic is a neutral choice here.

Beyond medications

  • Hydroxychloroquine — for essentially everyone, indefinitely. No drug-class page exists for it, but it is the backbone of lupus care: "Patients with systemic lupus should be prescribed hydroxychloroquine." It reduces flares, improves fatigue, reduces rash, improves arthralgias and arthritis, and confers a mortality benefit, and "should be continued indefinitely unless there is a contraindication or adverse event." It is the drug of choice for most cutaneous manifestations, first-line systemic therapy for discoid lupus, and given to all patients with lupus nephritis. In pregnancy it is continued, not stopped — it is considered safe, reduces disease activity and flare risk, and "has been shown to decrease the risk of fetal heart block."
  • The hydroxychloroquine eye rule — dose limit and screening schedule. The drug binds melanin in the retinal pigment epithelium and damages macular cones, and the damage does not necessarily stop when the drug does: the FDA label warns that "retinal changes and visual disturbances may progress even after cessation of therapy." That is the entire argument for screening: it has to find the damage early. The dose is bounded for exactly that reason: EULAR 2023 recommends hydroxychloroquine for all patients with lupus "at a target dose 5 mg/kg real body weight/day," and the labelled lupus dose is 200 mg once daily or 400 mg daily. Screening, per the FDA label: a baseline eye exam within the first year of starting the drug (visual acuity, a central visual field and spectral-domain OCT); annual exams for patients at higher risk; and for patients without significant risk factors, annual retinal exams "can usually be deferred until five years of treatment." Named risk factors (FDA label): daily doses of 5 mg/kg of actual body weight or more, use for more than five years, renal impairment, tamoxifen, and concurrent macular disease. Other toxicities to know, from the StatPearls chloroquine and hydroxychloroquine toxicity chapter: QT and QRS prolongation and arrhythmias, depression and seizures, hypoglycemia in overdose, and hemolysis in G6PD deficiency.
  • Photoprotection, with numbers. Schedule activity to avoid direct sun; wear "lightweight, loose-fitting, dark clothing that covers as much skin as possible"; and use broad-spectrum UVA/UVB sunscreen at SPF at least 70 for chemical sunscreens and at least 50 for physical-blocker sunscreens. Sunscreen has a demonstrated mechanistic effect, protecting against upregulation of ICAM-1 messenger RNA. Photosensitizing medications are avoided.
  • Exercise, not rest — the evidence answer to "should I take it easy?" Three meta-analyses found exercise improved aerobic capacity and decreased fatigue and depressive symptoms while it did not affect disease activity. Paced, regular activity is the sourced recommendation; prescribed bed rest is not.
  • Psychological support and structured education are treatments. Psychological interventions were found efficacious for anxiety, depression, disease activity and stress — note that disease activity itself is on that list. Patient-education studies improved self-efficacy and medication adherence, and those "interventions were oftentimes managed and assessed by nurses, physiotherapists or occupational therapists." Support-group connection and counseling are named interventions, not extras.
  • Diet and comorbidity control. Higher intake of vitamin B6 and vitamin C was associated with lower disease activity, Mediterranean-diet adherence correlated with reduced cardiovascular risk, and adequate vitamin D intake is recommended. Statins are used in lupus nephritis for cardiovascular risk, and additional medicines manage high cholesterol and high blood pressure.
  • Pregnancy planning and obstetric management. Conception is planned with disease quiescent for 6 months or more; teratogenic medications are switched 4 to 6 months ahead. All pregnant patients are tested for antiphospholipid antibodies and anti-SSA/Ro and anti-SSB/La. Low-dose aspirin 81 mg from the first trimester for high preeclampsia risk or positive antiphospholipid antibodies without thrombosis; heparin for thrombotic or obstetric antiphospholipid syndrome; fetal echocardiography weekly or biweekly in the second trimester with a history of neonatal lupus, weekly after prior congenital heart block; and prompt dexamethasone for first- or second-degree fetal heart block. Thromboembolic CNS events with antiphospholipid syndrome require lifelong warfarin.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Read the activity labs as a set, not as separate results: rising anti-dsDNA with falling C3 and C4 is the flare signature, alongside CBC, creatinine and urinalysis.
Why: Low complement in lupus means complement is being consumed binding immune complexes — it is a marker that the type III reaction is currently running, not a deficiency. Anti-dsDNA correlates with activity and with nephritis specifically.
Check urinalysis and serum creatinine on schedule in every patient with lupus, whether or not they feel well, and quantify any proteinuria with a 24-hour collection or a spot protein-to-creatinine ratio.
Why: Lupus nephritis affects roughly 40% to 50% of patients, usually appears early, and "in the early stages of lupus nephritis, patients are often asymptomatic." Proteinuria, microscopic hematuria or red blood cell casts are how it is found — the patient cannot report it.
Treat new fever in a patient on immunosuppressants as infection until proven otherwise and report it, rather than attributing it to a flare.
Why: Serious and opportunistic infection is a leading cause of death in lupus, and flare and infection present identically — fever, fatigue, malaise. The two cannot be separated at the bedside, so the safer assumption is escalated.
Inspect the mouth at every assessment instead of asking whether it hurts, and inspect sun-exposed skin and the scalp.
Why: Oral ulcers in lupus are "often painless at first," so a patient will truthfully deny mouth pain while carrying active mucosal disease. Discoid lesions on the scalp cause permanent scarring alopecia, so finding them early is what prevents disfigurement.
Check blood pressure, lipids, weight and smoking status at every visit, and take chest pain in a young patient seriously.
Why: Cardiovascular disease is now the leading cause of death in lupus and accounts for about half of deaths in Western cohorts, with the accelerated atherosclerosis worsened by the glucocorticoids used to treat the disease.
Screen for depression, anxiety and cognitive change — and escalate new seizure, psychosis, acute confusion or a focal deficit immediately.
Why: Up to 20% of patients have neuropsychiatric lupus across 19 ACR-defined manifestations, and cerebrovascular disease may contribute to mortality in up to 15% of patients. Inflammatory CNS disease is treated with high-dose pulse corticosteroids and will not wait.
Interventions & safety
Take a complete medication history at every new lupus presentation, looking specifically for procainamide, hydralazine, isoniazid, minocycline, TNF inhibitors and immune checkpoint inhibitors.
Why: Drug-induced lupus is a reversible condition — "withdrawal of the offending medication usually leads to symptom resolution" over weeks to months, which makes discontinuation the cornerstone of management. Missing the drug means treating a curable illness as a lifelong one.
Expect hydroxychloroquine for essentially every patient, confirm the dose respects the 5 mg/kg real-body-weight target (labelled lupus dose 200–400 mg daily), and confirm a baseline eye exam (visual acuity, visual field and SD-OCT) is booked within the first year — with annual exams thereafter for patients at risk, deferrable until 5 years of treatment only if there are no significant risk factors.
Why: Hydroxychloroquine reduces flares and confers a mortality benefit, so it is continued indefinitely. But its retinal damage can progress even after the drug is stopped, and the FDA label names dose and duration together among the risk factors — so bounding the daily dose and screening on schedule are the two things that prevent permanent vision loss. The labelled screening exam pairs a central visual field with spectral-domain OCT.
Support the steroid taper as a clinical goal: anticipate reaching approximately 5 mg/day of prednisone-equivalent by about 6 months — the ACR-based regimen as reported by StatPearls, corroborated by EULAR 2023 — with immunosuppressants introduced to make that possible.
Why: Glucocorticoids exacerbate the accelerated atherosclerosis that is the leading killer in lupus, and add osteoporosis, glaucoma, cataracts, weight gain and diabetes. Steroid-sparing is a survival intervention in a patient facing decades of disease.
Ensure nephrology comanagement whenever lupus nephritis is suspected or confirmed, and prepare the patient for renal biopsy when proteinuria exceeds roughly 500 mg per 24 hours.
Why: Lupus nephritis should "always" be comanaged with a nephrologist, and the biopsy is not merely confirmatory — it sets the ISN/RPS class, and the class determines which induction regimen the patient receives.
For patients who are pregnant or planning pregnancy: confirm antiphospholipid, anti-SSA/Ro and anti-SSB/La testing is done, and confirm hydroxychloroquine is continued.
Why: Those antibodies change obstetric management — aspirin, heparin, and fetal echocardiography schedules — and congenital heart block risk rises from 1% to 2% in a first pregnancy to 17% in subsequent pregnancies. Stopping hydroxychloroquine in pregnancy is the error: continuing it decreases fetal heart block risk.
Coordinate the interprofessional team deliberately — rheumatology, primary care, pharmacy, physical and occupational therapy, social work and behavioral health.
Why: The sourced division of labor is explicit: nurses provide educational support, symptom management and point-of-care services; pharmacists handle medication therapy support and authorizations; therapists manage functional disability; behavioral health supports patients and families. "An interprofessional team is essential."
Patient teaching
Teach photoprotection with the actual numbers: broad-spectrum sunscreen at SPF 70 or higher for chemical and 50 or higher for physical blockers, dark loose-fitting clothing covering as much skin as possible, and activity scheduled away from direct sun.
Why: UV light increases apoptosis and releases the nuclear autoantigen that drives the flare cycle, and the resulting photosensitivity "may last for weeks to months." A single afternoon outdoors can cost the patient a season.
Teach flare recognition as the core self-management skill, including the renal warning signs: new high blood pressure, foamy urine, nocturia, and swelling of the legs or face.
Why: "Being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe," and recognizing early organ involvement enables timely intervention. The renal signs matter most because they arrive late — the patient must understand that scheduled labs, not symptoms, protect the kidney.
Answer the fatigue question with the evidence: paced, regular exercise — not bed rest.
Why: Exercise decreased fatigue and depressive symptoms and "did not affect disease activity," with no worsening of disease activity documented across the studies reviewed. Prescribing rest for lupus fatigue is a myth this page deliberately corrects.
Teach that hydroxychloroquine is taken indefinitely, including on good days and during pregnancy — at the prescribed dose and no more, since the target is about 5 mg/kg of real body weight a day — and that eye screening continues for as long as the drug does.
Why: It reduces flares, improves fatigue and rash, and carries a mortality benefit — none of which continue if the drug stops. But dose and duration are both named risk factors for irreversible retinal damage (FDA label), so taking extra on a bad day is not a harmless shortcut, and annual eye exams are not optional once 5 years have passed. Education interventions have demonstrably improved adherence, which is why this is a teaching item rather than an assumption.
Discuss smoking cessation explicitly, and connect the patient to support for it.
Why: Smoking "exacerbates SLE activity, and cessation must be strongly encouraged," and cessation is associated with lower disease activity — one of the few levers the patient holds that changes the disease itself rather than only the symptoms.
Name body image, mood and stigma out loud, and refer to counseling and peer support rather than waiting to be asked.
Why: Permanent scarring, dyspigmentation and alopecia cause "significant reduction in quality of life, depression, and anxiety," psychiatric complications are common, and psychological interventions are efficacious for anxiety, depression, stress and disease activity. This is treatment, not comfort.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues cluster across four organ systems at once, which is itself the diagnostic signal. Skin: a photodistributed malar rash appearing days after sun exposure that spares the nasolabial folds, plus painless palate ulcers she only knew about when you looked. Joints: symmetric small-joint inflammation without erosions. Blood: leukopenia at 3,400 and thrombocytopenia at 96,000. Kidney: a blood pressure that has climbed from 112/70 to 148/92, nocturia, tight rings — and 3+ proteinuria with red blood cell casts. The serology completes it: ANA 1:640, anti-dsDNA and anti-Sm both positive, C3 and C4 both low. The misleading prior label was "rosacea" — and the nasolabial sparing is exactly what argues against it.

  2. 2
    Analyze cues

    Read the labs as a set and they tell one story. Low C3 and C4 are consumption, not deficiency — complement is being used up binding immune complexes, so the type III reaction is running right now. Anti-dsDNA is over 95% specific and correlates with nephritis; anti-Sm is 99% specific. The ANA is the entry criterion at 1:80 or above, and it is the sensitive test, not the diagnostic one — a positive ANA alone would prove nothing, but here it is the gateway to a picture that is already assembled. The 2019 EULAR/ACR criteria are organised into weighted clinical and immunologic domains, and she clears the 10-point threshold on the immunologic domain alone — anti-dsDNA or anti-Sm carries 6 points and low complement 4 — with clinical criteria present in abundance and the mandatory ANA entry criterion met. Resist the urge to run a line-by-line total: the domain rules govern which items actually count, the StatPearls carrier prints the item weights but not those rules, and the criteria paper itself was not fetched. And the red blood cell casts with 3+ protein are the finding that changes the whole plan: this is lupus nephritis, and it is the version that was silent until the blood pressure moved.

  3. 3
    Prioritize

    The kidney outranks everything else in the room. Roughly 10% to 30% of patients with lupus nephritis reach end-stage kidney disease within 10 years, and this patient has active urinary sediment with rising blood pressure at age 24 — the window in which the class is determined and induction started is now. Second priority is the rest of the systemic disease and getting hydroxychloroquine started, since it goes to all patients including all patients with nephritis. Third is the teaching that prevents the next flare — photoprotection above all. The rash, which is what brought her in and what she cares about most, is the least urgent item on the list, and the conversation has to acknowledge that without dismissing it.

  4. 4
    Generate solutions

    Escalate for urgent nephrology comanagement and renal biopsy — biopsy is indicated with proteinuria above roughly 500 mg per 24 hours, persistent dysfunction, or active sediment, and she has active sediment already. Anticipate quantified proteinuria by 24-hour collection or spot ratio. Anticipate hydroxychloroquine started now, with the dose kept to the 5 mg/kg real-body-weight target and a baseline eye exam (visual field and SD-OCT) booked within the first year. Anticipate that if the biopsy shows Class III or IV disease, induction will be triple therapy: glucocorticoids with mycophenolate plus belimumab or a calcineurin inhibitor such as voclosporin, or a cyclophosphamide-based regimen — and that the steroid will be tapered toward about 5 mg/day by six months. Plan the pregnancy conversation early: she is 24, and the rules about disease quiescence, medication switching and antibody testing need to be in place before, not during, a pregnancy.

  5. 5
    Take action

    Document the full multisystem picture including the findings she did not report — the painless ulcers and the blood pressure trend. Call rheumatology and nephrology together rather than sequentially. Start the teaching that cannot wait: photoprotection with SPF 70 or higher chemical / 50 or higher physical sunscreen and covering clothing, because the beach trip is the mechanism, not the coincidence. Explain why the kidney is the priority when her face is what bothers her. Two traps to avoid here. First, treating the positive ANA as the diagnosis — its specificity is only about 20%, and it would be equally positive in several other conditions; it is the negative ANA that is powerful, because it makes lupus highly unlikely. Second, reassuring her that her kidneys must be fine because she feels fine — early lupus nephritis is asymptomatic by nature, and the casts in her urine are the whole point.

  6. 6
    Evaluate

    Success over the coming months looks like: biopsy done and the ISN/RPS class known, induction started with nephrology comanaging, hydroxychloroquine running at the 5 mg/kg real-body-weight target with the baseline eye exam completed, blood pressure back under control, and proteinuria trending down toward the 0.7 to 0.8 g/24 h one-year mark that predicts good long-term renal prognosis. The steroid should be approaching 5 mg/day by about six months, and if it is not, that is a signal to add or escalate a steroid-sparing agent rather than to accept the dose. Re-escalation triggers are set now: a new fever on immunosuppressants is infection until proven otherwise; a new seizure, psychosis or focal deficit is an emergency; a new clot is a disease manifestation, not bad luck. And the follow-up she must not skip is the one where nothing hurts — because that is when the kidney is checked.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Rheumatology clinic, first visit after an urgent-care referral · 0930

A 24-year-old woman referred after two urgent-care visits in three weeks. She returned from a week at the beach a month ago, and a red rash appeared across her cheeks within days and has not fully settled. Since then she has had aching hands and wrists that are worst in the morning, profound fatigue, and intermittent low-grade fevers. She was treated for "rosacea and a viral illness." She mentions she has been "peeing a lot at night" and that her rings feel tight.

0930 vitals — HR 88 · BP 148/92 (previously 112/70 at a clinic visit last year) · RR 16 · T 37.9 °C
Skin & mucosa — raised erythema over both cheeks and the nasal bridge, sparing the nasolabial folds; two shallow ulcers on the hard palate that she says she cannot feel
Musculoskeletal — symmetric tenderness and soft swelling of the MCP and PIP joints of both hands and both wrists; no deformity; no erosive changes on hand films
Labs — ANA positive 1:640 · anti-dsDNA positive · anti-Sm positive · C3 and C4 both low · WBC 3,400/mm³ · platelets 96,000/mm³ · creatinine 1.1 mg/dL
Urinalysis — 3+ protein · microscopic hematuria · red blood cell casts present · spot protein-to-creatinine ratio pending
Q1 Select all that apply
Which findings require prompt escalation today? Select all that apply.
  1. A. Red blood cell casts with 3+ proteinuria on urinalysis
  2. B. Blood pressure 148/92, up from 112/70 a year ago
  3. C. C3 and C4 both low
  4. D. Malar erythema sparing the nasolabial folds
  5. E. Two painless ulcers on the hard palate
Reveal answer & rationale
Answer: A, B
Every option here is abnormal and every one belongs in the documentation — but only two demand action today. Red blood cell casts with heavy proteinuria (A) signal active lupus nephritis, the organ-threatening problem in this room, and 10% to 30% of patients with nephritis reach end-stage kidney disease within 10 years. The blood-pressure trend from 112/70 to 148/92 (B) is a renal warning sign rather than an isolated vital, and it points at the same kidney. The other three are diagnostically important and not urgent: low C3 and C4 (C) confirm complement consumption and active disease, but they change the diagnosis rather than today’s plan; the malar rash (D) is the distinctive cutaneous sign and carries classification weight, yet acute cutaneous lupus heals without scarring — it is the least urgent item in the scenario; and the painless palate ulcers (E) matter because they are found by inspection rather than by asking, but they are not an escalation trigger.
Q2 Multiple choice
A student nurse says, "Her ANA is positive at 1:640 — that confirms lupus." The best response is:
  1. A. "Correct — a positive ANA at that titer is diagnostic of SLE."
  2. B. "The ANA is very sensitive but only about 20% specific — it is an entry criterion, not a diagnosis. It is a negative ANA that is powerful, because it makes lupus highly unlikely."
  3. C. "The ANA is unhelpful in lupus; only anti-dsDNA and anti-Smith matter."
  4. D. "A positive ANA rules out lupus and points toward another connective tissue disease."
Reveal answer & rationale
Answer: B
The two numbers are the whole teaching point: ANA sensitivity is greater than 97% while specificity is only about 20%, so a positive result "is not diagnostic, but a negative result makes SLE highly unlikely" (B). That is why ANA positivity at 1:80 or above is the entry criterion for classification rather than the conclusion. Option A is the classic error — a high titer is still a screening result. Option C overcorrects: ANA is not unhelpful, it is the gateway test, and without it the 2019 EULAR/ACR criteria cannot even be applied. Option D inverts the finding entirely; a positive ANA raises the possibility rather than excluding it, though it also appears in other autoimmune disorders and in healthy people.
Q3 Put in order
Put the nurse’s priorities in order:
  1. A. Begin teaching on photoprotection and flare recognition
  2. B. Escalate for nephrology comanagement and anticipate renal biopsy for the active urinary sediment
  3. C. Reinforce that the facial rash will improve with treatment and discuss cosmetic concerns
  4. D. Confirm hydroxychloroquine is started at the 5 mg/kg real-body-weight target and the baseline eye examination is booked
Reveal answer & rationale
Correct order: B → D → A → C
Active lupus nephritis is the organ-threatening problem and outranks everything else, so escalation and biopsy planning come first (B) — the biopsy sets the ISN/RPS class, and the class sets the induction regimen. Hydroxychloroquine (D) follows immediately because it goes to all patients with lupus including all patients with nephritis, and the baseline eye exam is booked within the first year. Photoprotection and flare-recognition teaching (A) is genuinely preventive — the beach trip is the mechanism behind this presentation — but it prevents the next flare rather than treating this one. Addressing the rash cosmetically (C) matters to the patient and must not be dismissed, but it is the least urgent clinical item; permanent disfigurement risk belongs to discoid lesions, not to the malar rash, which heals without scarring.
Q4 Multiple choice
The patient is started on prednisone and mycophenolate mofetil. Two weeks later she calls reporting a temperature of 38.4 °C, fatigue and aching. The nurse should recognize that:
  1. A. This is an expected lupus flare and she should increase her prednisone at home
  2. B. Fever in a patient on immunosuppressants is infection until proven otherwise and must be evaluated — flare and infection present identically
  3. C. Fever is an expected side effect of mycophenolate and needs no action
  4. D. She should stop both medications until the fever resolves
Reveal answer & rationale
Answer: B
Serious and opportunistic infection is a leading cause of morbidity and mortality in lupus, arising from both immune dysfunction and immunosuppressive therapy — and flare produces the same fever, fatigue and malaise, so the two genuinely cannot be separated at the bedside (B). Self-escalating prednisone (A) would deepen immunosuppression in a patient who may be septic, and dose changes are not a patient-initiated decision. Calling it an expected drug effect (C) dismisses the single most dangerous ambiguity in lupus care. Stopping both medications (D) is also wrong: abrupt discontinuation risks a flare and does nothing to treat an infection — the answer is evaluation, not unilateral change.
Q5 Multiple choice
The patient says, "I read that I should rest as much as possible because exercise causes lupus flares." The best response is:
  1. A. "That is right — activity increases inflammation, so rest is the safest approach during a flare."
  2. B. "Exercise is only safe once your labs are completely normal."
  3. C. "The evidence shows exercise reduces fatigue and depressive symptoms without affecting disease activity — paced, regular activity is recommended."
  4. D. "Exercise makes no difference either way, so it is entirely your preference."
Reveal answer & rationale
Answer: C
Three meta-analyses found that exercise improved aerobic capacity and decreased fatigue and depressive symptoms while it "did not affect disease activity," with no worsening of disease activity documented across the studies reviewed (C). Option A is the specific myth this page corrects — prescribing rest for lupus fatigue is not supported. Option B invents a precondition that no source states and would leave most patients sedentary indefinitely, since labs fluctuate. Option D understates a real, measured benefit; fatigue is among the most disabling features of lupus, so an intervention that reduces it is not a matter of preference.

Common questions

What causes systemic lupus erythematosus?
Common causes and risk factors include female sex — a 9 to 1 female-to-male ratio, predominantly affecting women of childbearing age, with risk falling after menopause, black race — the highest rates, with greater disease severity and earlier onset; then asian and hispanic, then white populations, male sex as a severity modifier — less common, but "lupus in men tends to be more severe" and male sex is a poor prognostic factor, x-chromosome dosage — risk is 14-fold higher in klinefelter syndrome (47,xxy), ultraviolet radiation and sun exposure — the best-established flare trigger, acting by increasing apoptosis, and others.
What are the early signs of systemic lupus erythematosus?
Early findings include Fatigue, malaise, fever, anorexia and weight loss — present in more than 90% of patients.
Which findings should a nurse report immediately in systemic lupus erythematosus?
Report immediately: A new clot — deep vein thrombosis, pulmonary embolism, or an arterial event, New seizure, psychosis, acute confusion or a focal neurologic deficit, Cardiovascular disease — now the leading cause of death, Serious and opportunistic infection. These signal deterioration that needs rapid intervention.
Does a positive ANA mean you have lupus?
No. The ANA is the screening test and the classification entry criterion, with sensitivity above 97% but specificity of only about 20% — it is positive in other autoimmune disorders and in healthy people. The sourced framing is deliberately asymmetric: a positive ANA "is not diagnostic, but a negative result makes SLE highly unlikely." The antibodies that carry diagnostic weight are the specific ones — anti-dsDNA (over 95% specific) and anti-Smith (99% specific) — which is why they score 6 points in the 2019 EULAR/ACR criteria while the ANA merely opens the door. And even the full criteria set was "developed for research studies": lupus remains "a clinical diagnosis made by an expert."
Why are complement levels low in a lupus flare?
Because the complement is being used up, not because the patient cannot make it. Lupus is a type III hypersensitivity reaction: immune complexes deposit in tissue and "activate the classical complement pathway, generating C3a and C5a," and "complement consumption results in low serum C3, C4, and CH50." So a falling C3 and C4 means the reaction is actively running — which is why low complement tracks disease activity and why the classic flare signature is rising anti-dsDNA with falling C3 and C4, checked together rather than separately.
Why does lupus nephritis need scheduled testing when the patient feels fine?
Because feeling fine is the normal state of early lupus nephritis. It affects roughly 40% to 50% of patients with SLE, usually appears early in the disease, and "in the early stages of lupus nephritis, patients are often asymptomatic." By the time the sourced symptoms show up — new hypertension, foamy urine, nocturia, leg edema, rising creatinine — inflammation has been running in the glomerulus for some time. Detection is by urinalysis and creatinine: proteinuria, microscopic hematuria, or red blood cell casts. That matters because 10% to 30% of patients with lupus nephritis reach end-stage kidney disease within 10 years, and because proteinuria above roughly 500 mg per 24 hours is what triggers the renal biopsy that sets the ISN/RPS class — and the class determines the treatment.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.